ADCs targeting special cancers such as brentuximab vedotin for lymphoma,14, 15 inotuzumab for acute lymphoblastic leukemia,16, 17 gemtuzumab for acute myeloid leukemia,18, 19 polatuzumab20 and rituximab21 for B‐cell lymphoma, and ado‐trastuzumab emtansine for HER2‐positive breast cancer22, 23 have been approved by FDA for application. Here, ERBB2 is linked to cancer.